Biocept to Present at Four Virtual Investor Conferences in September

Rhea-AI Summary

Biocept (Nasdaq: BIOC) has announced that President and CEO Michael Nall will present at four upcoming investor conferences from September 13 to September 30, 2021. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference, Oppenheimer Fall Healthcare Life Sciences & MedTech Conference, Cantor Virtual Healthcare Conference, and Benzinga Healthcare Small Cap Conference. Presentations will be available for streaming on the company’s website and archived for 90 days. Biocept specializes in molecular diagnostics for cancer and COVID-19 testing.

SAN DIEGO--(BUSINESS WIRE)-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:

• H.C. Wainwright 23^rd Annual Global Investment Conference being held September 13-15, 2021. The presentation can be accessed on the Investor Relations section of the Biocept website beginning Monday, September 13, 2021 at 4:00 a.m. Eastern time (1:00 a.m. Pacific time).

• Oppenheimer Fall Healthcare Life Sciences & MedTech Conference on Wednesday, September 22, 2021 at 3:45 p.m. Eastern time (12:45 p.m. Pacific time).

• Cantor Virtual Healthcare Conference on Wednesday, September 29, 2021 at 4:40 p.m. Eastern time (1:40 p.m. Pacific time).

• Benzinga Healthcare Small Cap Conference on Thursday, September 30, 2021 at 2:20 p.m. Eastern time (11:20 a.m. Pacific time). The presentation will be available on the Benzinga website here.

Webcasts of the presentations at the Oppenheimer and Cantor conferences will be available on the Events and Presentations page of the Biocept website and will be archived for 90 days.

About Biocept

Biocept, Inc., develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer. In addition to its broad portfolio of blood-based liquid biopsy tests, the company has developed the CNSide cerebrospinal fluid assay, designed to diagnose cancer that has metastasized to the central nervous system. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide RT-PCR-based COVID-19 testing and services to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005034/en/

Investors:

Jody Cain, LHA Investor Relations

Jcain@lhai.com, 310-691-7100

Media:

Andrea Sampson, Sampson PR Group

asampson@sampsonprgroup.com, 562-304-0301

Source: Biocept

FAQ

What conferences will Michael Nall present at for Biocept in September 2021?

Michael Nall will present at the H.C. Wainwright Global Investment Conference, Oppenheimer Fall Healthcare Life Sciences & MedTech Conference, Cantor Virtual Healthcare Conference, and Benzinga Healthcare Small Cap Conference.

When is the H.C. Wainwright Global Investment Conference for Biocept?

The H.C. Wainwright Global Investment Conference will be held from September 13 to September 15, 2021.

Where can I access Biocept's conference presentations?

Conference presentations by Biocept will be available on their Investor Relations website starting September 13, 2021.

What is Biocept's focus in molecular diagnostics?

Biocept specializes in molecular diagnostic assays for cancer diagnosis, treatment monitoring, and RT-PCR-based COVID-19 testing.

How long will the webcasts of Biocept's presentations be available?

The webcasts of Biocept's presentations will be available for 90 days after the events.